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Abstract
Receipt of a living donor liver transplant (LDLT) has been associated with improved survival
compared with waiting for a deceased donor liver transplant (DDLT). However, the survival
benefit of liver transplant has been questioned for candidates with model for end-stage liver
disease (MELD) scores< 15, and the survival advantage of LDLT has not been demonstrated
during the MELD allocation era, especially for low MELD patients. Transplant candidates
enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study after 02/28/02
were followed for a median of 4.6 years. Starting at the time of presentation of the first potential
living donor, mortality for LDLT recipients was compared to mortality for patients who remained
on the waiting list or received DDLT (no LDLT group) according to categories of MELD score
(<15 or 15+) and diagnosis of hepatocellular carcinoma (HCC). Of 868 potential LDLT recipients
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(453 with MELD<15; 415 with MELD 15+ at entry), 712 underwent transplantation (406 LDLT;
306 DDLT), 83 died without transplant, and 73 were alive without transplant at last follow-up.
Overall, LDLT recipients had 56% lower mortality (hazard ratio (HR)=0.44, 95% confidence
interval [CI] 0.32–0.60; p<0.0001). Among candidates without HCC, mortality benefit was seen
both with MELD<15 (HR=0.39;p=0.0003) and MELD 15+ (HR=0.42;p=0.0006). Among
candidates with HCC, a benefit of LDLT was not seen for MELD<15 (HR=0.82, p =0.65) but was
seen for MELD 15+ (HR=0.29, p=0.043).
Conclusions—Across the range of MELD scores, patients without HCC derived a significant
survival benefit when undergoing LDLT rather than waiting for DDLT in the MELD liver
allocation era. Low MELD candidates with HCC may not benefit from LDLT.
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Following the introduction of adult-to-adult living donor liver transplantation (LDLT) in the
U.S. in the late 1990’s the procedure gained in popularity, and in 2001 represented
approximately 8% of all adult liver transplants performed in the U.S. Subsequently, use of
the procedure declined from 412 cases in 2001 to 168 LDLT in the U.S in 2009
(www.optn.transplant.hrsa.gov accessed 08/13/10). Previous retrospective reports by the
Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) identified a
survival benefit for patients who received LDLT as compared to waiting for, or receiving, a
deceased donor liver transplant (DDLT).(1)That report employed data accrued over the early
years of LDLT in nine active liver transplant centers in the U.S. More than 70% of the
potential liver transplant recipients enrolled in that retrospective cohort study were evaluated
in the era before the Model for End-Stage Liver Disease (MELD) score was employed for
deceased donor liver allocation in the U.S. (February 28, 2002), and thus the benefits of
pursuing LDLT as compared to waiting for deceased donor liver transplant (DDLT) in the
MELD allocation era are not well understood.
Moreover, there is considerable uncertainty regarding which populations of adult liver
transplant candidates benefit most from receipt of LDLT in comparison to awaiting DDLT.
Markov modeling suggested benefit associated with receipt of LDLT in patients with
hepatocellular carcinoma (HCC) (2,3) compared with waiting for DDLT. Experience from
A2ALL, however, demonstrated higher rates of post-transplant recurrence in liver transplant
candidates with HCC who underwent LDLT(4). Similarly, there is uncertainty regarding
whether there is a survival benefit associated with receipt of LDLT among transplant
candidates with MELD<15. Two recent large database analyses of the U.S liver transplant
population have suggested that a survival benefit is obtained by transplant candidates
undergoing transplantation with MELD scores in excess of 15(5) or 12(6) in comparison to
remaining on the waiting list. Analyses from the retrospective cohort study reported by
A2ALL suggested a survival benefit for transplant candidates enrolled in A2ALL with
laboratory (non-exception) MELD scores less than 15, although the majority of those
patients were actually transplanted in the pre-MELD allocation era (1).
To resolve some of the uncertainties delineated above, and better inform liver transplant
candidates regarding transplant outcomes in the current allocation paradigm, we examined
data from A2ALL for liver transplant candidates who entered into the study following the
introduction of the MELD-based liver allocation system on February 28, 2002 through
August 31, 2009. Outcomes for these patients who presented to A2ALL transplant centers
with their first potential living donor during this period were analyzed in order to assess the
potential benefit of receipt of LDLT based on transplant candidate MELD score and
presence or absence of HCC. The study design, which examined patient outcomes from the
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time of first living donor evaluation, was created to allow clinicians to counsel transplant
candidates and their donors when the opportunity for LDLT presented itself in the transplant
clinic setting.
PATIENTS AND METHODS
A primary objective of the A2ALL study has been to identify transplant candidates who
accrue a survival benefit from adult living donor liver transplant. In order to encompass both
pre-transplant events and post-transplant survival, patient entry into the study occurred on
the date that each potential LDLT candidate’s first potential living donor presented for initial
donor history and physical examination at one of the nine A2ALL transplant centers, as
previously described (1).
Data sources
Liver transplant candidate and potential donor data were provided by the participating
A2ALL transplant centers based on a common protocol. Chart reviews and prospective data
collection were supplemented by additional ascertainment of deaths and transplants through
the end of 2008 for patients included in the retrospective study only (n=112) and through
February 2010 for the remaining patients (n=756) under a data use agreement with the
Scientific Registry of Transplant Recipients (SRTR). The study cohort utilized for this
report included 868 adult liver transplant candidates for whom the first living liver donor
was evaluated between February 28, 2002 and August 31, 2009. For these candidates,
median follow-up was 4.6 years (range 4 days-7.9 years). Data from DDLT recipients not
enrolled in A2ALL but transplanted at A2ALL centers were obtained from SRTR for
comparison with A2ALL patients who received DDLT during the same period.
Statistical methods
The cumulative incidence function was calculated using SAS macro “comprisk”(7). The
MELD scores reported were calculated on laboratory data only(8), and ignored MELD
exception scores used in organ allocation.
Survival analyses, starting at the time of evaluation of each subject’s first potential donor,
were employed to compare mortality after LDLT to the conventional transplant strategy of
waiting for and potentially receiving DDLT. The non-LDLT group thus included those who
received DDLT, those who remained on the waitlist without receiving a liver transplant at
study end, and those who died prior to receiving a DDLT. LDLT (n=4) or DDLT (n=2)
procedures that were aborted intra-operatively due to recipient conditions were considered to
be transplants. Domino transplants were classified as DDLTs (n=1).
A Cox regression method employing sequential stratification to compare the effect of receipt
of LDLT with not receiving LDLT over the entire period of observation was utilized for the
primary analysis(1). The sequentially stratified Cox model was adjusted for baseline
covariates of age, HCC, HCV, cholestatic liver disease, and MELD score, all determined at
the time of first donor evaluation. Multiplicative interactions (effect modification) between
LDLT, HCC, and MELD score were evaluated. An additional Cox regression analysis of
post-transplant mortality was performed starting on the day of transplant, and compared
LDLT vs. DDLT adjusted for age, HCC, HCV, cholestatic liver disease, and MELD score at
transplant.
Survival probabilities in the tables and figures were calculated in the following manner.
Survival in the absence of receipt of LDLT was estimated from a Cox regression censored at
LDLT. This model was adjusted for age, HCC, HCV, cholestatic disease, and MELD score
as above. Depiction of probabilities of survival that encompass both the waiting period for
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liver transplantation and post-transplant period were estimated by multiplying the waitlist
survival probability at the respective LDLT median transplant time by the post-transplant
survival probability for LDLT recipients. Transplant and survival experiences are shown
over the five years from initial donor evaluation, during which time 88% of all patient
follow-up and 93% of all deaths occurred. All analyses were performed utilizing SAS 9.2
software (SAS Publishing, Cary, NC: SAS Institute Inc., 2008).
Human subjects protection
The Institutional Review Boards and Privacy Boards of the Data Coordinating Center and
the nine participating transplant centers approved the study.
RESULTS
Characteristics at study entry and at transplant
A total of 868 adult transplant candidates were enrolled in the A2ALL study between
February 28, 2002 and August 31, 2009. The clinical characteristics of these candidates,
measured closest to the time of the evaluation of the first potential living donor, are
presented in Table 1 according to MELD<15 (n=453) or 15+ (n=415) and subsequent
receipt of LDLT. Among candidates with MELD<15, LDLT recipients, compared with non-
LDLT recipients, were significantly (p<0.05) more likely to be white, have cholestatic liver
disease, or biliary atresia, and to have a history of upper abdominal surgery. They were less
likely to have a diagnosis of hepatitis C or HCC. Among candidates with MELD 15+, LDLT
recipients were more likely to have advanced HCC and diagnosis of “other” liver disease.
For those transplant candidates with a MELD <15 at the time of study entry, the mean
MELD score of those who ultimately received LDLT, was not significantly different from
those who received a DDLT or no transplant (Table 1, p=0.66). However, mean MELD at
transplant was higher for DDLT recipients than for LDLT recipients (p=0.004). For those
transplant candidates with a MELD 15+ at study entry, the mean MELD at entry was lower
for those patients who ultimately received an LDLT compared to those who did not
(p=0.01). The mean MELD at transplant for recipients of LDLT in this group was much
lower than the mean MELD at time of transplant for recipients of DDLT (p<0.0001), an
observation reflecting the need for MELD scores to rise in order to receive priority for
DDLT.
Outcomes based on MELD score at study entry
Of those transplant candidates with MELD score<15 at enrollment, 224 received LDLT,
while 123 received DDLT and 106 did not receive a transplant. Of this latter group, 49
(46%) died on the waitlist without receiving a transplant of any type. Of those transplant
candidates with MELD 15+ at enrollment, 182 received LDLT, while 183 received DDLT
and 50 did not receive a transplant during the study period. Of this latter group, 34 (68%)
died on the waitlist without receiving any transplant.
Overall, LDLT recipients had 56% lower mortality (hazard ratio (HR)=0.44, 95%
confidence interval [CI] 0.32–0.60; p<0.0001). The probability of receiving an LDLT,
receiving a DDLT, or dying on the waitlist, over the five years from the time of initial donor
evaluation is shown in Figure 1a for those candidates with MELD<15 at study entry and in
Figure 1b for those candidates with MELD 15+ at study entry.
Mortality in candidates without HCC
Mortality based on MELD score at enrollment—In an adjusted sequential
stratification analysis of time from initial donor evaluation to death for transplant candidates
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with MELD < 15 and no HCC at study entry, patients who underwent LDLT had a mortality
hazard ratio [HR] of 0.39 (95% confidence interval [CI] 0.24–0.65; p=0.0003), compared
with patients who did not receive LDLT (Figure 2). For these candidates, the median time to
receipt of LDLT was 3.0 months after the first potential living liver donor evaluation, while
the time to receipt of DDLT was 7.9 months. For patients with MELD 15+ at study entry
and no HCC, patients who underwent LDLT had a lower mortality than those who did not
receive LDLT (HR=0.42, 95% CI 0.26–0.69; p=0.0006) (Figure 2). For this group of
candidates without HCC and a MELD score of 15+ at study entry, the median time to receipt
of LDLT was 2.5 months, while the time to receipt of DDLT was 3.0 months, after the first
potential living liver donor evaluation. We performed additional analyses to look at smaller
subsets of transplant candidates based on MELD score at enrollment to examine consistency
of results across categories of MELD scores. For MELD scores of 6–10, 11–14, 15–19, and
20+, there was a nearly constant survival advantage for LDLT across categories, with a
range in hazard ratios of 0.38 to 0.44 (Table 2).
Survival from the time of transplantation—While not the primary focus of the
A2ALL study, analyses of survival were also performed beginning at the time of transplant
(rather than at the time of first donor evaluation) to compare mortality following LDLT and
DDLT. Post-transplant mortality risk was similar following LDLT and DDLT. Specifically,
the mortality hazard ratio for LDLT compared to DDLT was 0.88 (p=0.78) for non-HCC
candidates with MELD<15 at evaluation and 0.83 (p=0.60) for non-HCC candidates with
MELD 15+ at evaluation, adjusted for MELD at transplant, age, and diagnoses of hepatitis
C, and cholestatic liver disease.
Transplant candidate morbidities—We used data from SRTR and A2ALL to explore
the possibility that candidates for whom LDLT was considered were inherently more ill than
candidates not considered for LDLT at the A2ALL centers. The presence of these
complications was determined based on SRTR data alone, regardless of whether the patient
was enrolled in A2ALL or not. Three comparisons were made between patients enrolled in
A2ALL and listed liver transplant candidates at the nine A2ALL centers who were not
enrolled in A2ALL: liver disease complications at time of listing (hepatic encephalopathy,
ascites, variceal hemorrhage, upper abdominal surgery, spontaneous bacterial peritonitis,
hyponatremia (Na < 135 mEq/L) and transjugular intrahepatic portosystemic shunt
(TIPSS)), donor risk index at transplantation(9), and post-transplant survival. The frequency
of complications was similar between patients enrolled in A2ALL and listed liver transplant
candidates at the nine A2ALL centers who were not enrolled in A2ALL. Although
significantly more of those not enrolled in A2ALL had TIPSS in the MELD<15 group (5.1%
non-A2ALL vs. 2.6% in A2ALL, p<0.01) and more had ascites in the MELD 15+ group
(89% non-A2ALL vs. 85% in A2ALL, p=0.03). There were no significant differences in
frequency of the remaining complications (for MELD<15, p>0.12 for all except TIPSS; for
MELD 15+, p>0.13 for all except ascites).
DDLT donor risk index—We compared donor risk index (DRI)(9) for DDLT recipients
enrolled in A2ALL and DDLT recipients from the same centers but not enrolled in A2ALL.
Median DRI for non-HCC DDLT recipients with MELD<15 at listing enrolled in A2ALL
was 1.35 and was 1.40 for 1458 DDLT recipients not enrolled in A2ALL with MELD<15 at
listing who were transplanted at the nine participating centers (p=0.94). For non-HCC
DDLT recipients with MELD15+ at listing, the median DRI was 1.33 for A2ALL patients
and 1.34 for 2999 non-A2ALLenrolled DDLT recipients (p=0.45).
Post-transplant outcomes—Finally, we compared post-DDLT mortality for non-HCC
DDLT recipients. For non-HCC patients with MELD<15 at listing, post-DDLT mortality
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HR was 0.79 (p=0.23) for A2ALL patients compared with non-A2ALL-enrolled patients.
For non-HCC patients with MELD15+ at listing, post-DDLT mortality HR was 1.00
(p=0.98) for A2ALL patients compared to non-A2ALL-enrolled patients. These analyses
were adjusted for recipient age, MELD at transplant, and DRI.
Mortality in candidates with HCC
One hundred thirty of 868 (15.0%) of the A2ALL transplant candidates carried a diagnosis
of HCC at the time of enrollment. Of these, 93 had a laboratory (non-exception) MELD<15
at study entry and 37 had MELD15+ at study entry. Tumor stages at the time of study entry
are presented in Table 1 for these two groups of transplant candidates.
Among the 93 transplant candidates in the MELD<15 group, 32 HCC patients received
LDLT at a median of 1.6 months after initial living liver donor evaluation, 49 received
DDLT at a median of 2.2 months after study entry, and 12 had not undergone any transplant
by last follow-up, including seven who died on the waitlist. Among the 37 transplant
candidates in the MELD15+ group, 17 HCC patients went on to receive LDLT at a median
of 1.8 months after initial living donor evaluation, 16 received DDLT at a median of 3.1
months after first living donor evaluation, and four had not undergone any transplant at last
follow-up, three of whom died on the waitlist.
In an adjusted sequential stratification analysis of time from initial donor evaluation to death
for transplant candidates with MELD<15 and HCC at study entry, we were unable to detect
a significant survival benefit for LDLT recipients compared to patients who did not receive
LDLT (HR=0.82, 95% CI 0.36–1.89; p=0.65). In a similar analysis for patients with
MELD15+ at study entry and HCC, patients who underwent LDLT had significantly lower
mortality risk than those who did not receive LDLT (HR=0.29, 95% CI 0.09–0.96;
p=0.043). When analysis was restricted to those candidates with HCC (adjusted for MELD
at transplant, age at transplant, HCV infection and cholestatic liver disease) who actually
received either DDLT or LDLT, post-transplant survival did not differ between recipients of
LDLT or DDLT. For candidates with MELD less than 15 at enrollment and HCC the HR
was 2.17 (vs. DDLT), p=0.19. For candidates with MELD 15+ at enrollment and HCC, the
HR was 1.10 (vs. DDLT), p=0.91.
DISCUSSION
There is considerable uncertainty regarding the benefit of liver transplantation in adult
candidates with low MELD scores. Prior work demonstrated little or no net survival benefit
for transplant candidates with low MELD scores (MELD<15) who received deceased donor
liver transplant in the U.S.(5). This observation resulted in a major change in deceased donor
liver allocation policy in the U.S., termed Share15, in a manner that markedly limited the
opportunity for receipt of DDLT for adult candidates with low MELD scores. Subsequent
analysis employing SRTR data suggested a positive transplant benefit (incorporating pre-
transplant and post-transplant mortality risk measures) for transplant candidates at somewhat
lower MELD scores(6). The majority of liver transplant candidates with MELD scores of 12
or greater would benefit by liver transplantation based on that analysis. Timely receipt of
DDLT for such liver transplant candidates with MELD scores of 12–15, however, is
unlikely in the setting of allocation policies that preferentially offer DDLT to candidates
with the highest MELD scores in order to minimize waitlist mortality. For example, in the
current analysis, only 42% of candidates with MELD< 15 who did not undergo LDLT
received DDLT within 12 months of donor evaluation.
An alternative strategy to achieve timely transplantation for candidates with lower MELD
scores is LDLT. The A2ALL consortium enrolled a large cohort of patients with low MELD
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scores for whom LDLT was an option, and thus analysis of patients enrolled in this study
provided an opportunity to ascertain whether LDLT in patients with low MELD offers
transplant survival benefit. As detailed above, receipt of LDLT in candidates without HCC
whose MELD scores were less than 15 at time of study enrollment was associated with
significant survival advantage in comparison to waiting for, or receiving, DDLT. Such
benefit could be the result of either diminished waitlist mortality, or improved post-
transplant survival. As post-transplant survival was similar in both LDLT and DDLT
recipients in the MELD<15 group, the net survival benefit must be attributed largely to
reduced waitlist mortality. Although low MELD scores have been associated with relatively
low risk of death at 90 days and one year(10–12), 10.8% of low MELD patients died on the
waitlist at a median of 9.8 months following entry into this cohort. This number
approximates the percentage difference in estimated 3-year mortality between the LDLT
recipients and non-LDLT recipients (Figure 2). Avoidance of waitlist deaths as a
consequence of timely transplant, as reflected by a median wait for LDLT of 3.0 months
after study entry, thus appears to be the major contributor to favorable outcomes in the low
MELD group. Additional support for the notion that the primary survival benefit associated
with LDLT is avoidance of waitlist mortality is derived from analysis of outcomes in the
candidates with HCC with MELD <15. LDLT was not associated with significant survival
benefit in this group, for whom waiting time for LDLT (median 1.6 months) was only
slightly less than waiting time to DDLT (median 2.2 months).
We considered an alternative explanation for the survival benefit experienced by LDLT
recipients in the MELD<15 group and explored the possibility that the quality of the DDLT
grafts received by these patients was inferior, and resulted in higher post-transplant mortality
following DDLT. Three lines of evidence refute this speculation. First, as mentioned above,
post-transplant survival was not different in low MELD patients who received LDLT and
those who received DDLT (HR=0.96, p=0.91 for non-HCC recipients). Second, we
examined the DRI for the DDLT organs received by the low MELD candidates enrolled in
A2ALL, and compared that to the median DRI of high MELD patients receiving DDLT at
the participating centers. The median DRI for the DDLT organs received by the MELD<15
candidates without HCC who were enrolled in A2ALL was very similar to the median DRI
for DDLT organs transplanted during the post-MELD era into recipients at A2ALL centers
with MELD15+ at listing who had not enrolled in A2ALL. Most importantly, recipients of
DDLT enrolled in A2ALL did not have higher post-transplant mortality than non-A2ALL-
enrolled recipients of DDLT at the same centers.
As has been true throughout the history of LDLT, the survival benefits observed here for
LDLT recipients must be balanced by the risks of morbidity and mortality experienced by
LDLT donors. It must also be recognized that the A2ALL study does not reflect the
outcomes of a randomized trial of LDLT versus those listed for DDLT at the nine A2ALL
transplant centers. Rather, the study reports upon the observational outcomes experienced by
transplant candidates for whom consideration of living liver donation was felt to be an
appropriate option by the treating transplant team, and was possibly available, based on the
presence of a donor presenting for evaluation at the participating transplant center. It could
be postulated that the candidates with low MELD scores for whom LDLT was seriously
entertained by our transplant centers represent a group of individuals with perceived
increased risk of mortality beyond that associated with their MELD score. This possibility
was explored by examining the frequency of hepatic encephalopathy, ascites, variceal
hemorrhage, previous upper abdominal surgery, spontaneous bacterial peritonitis,
hyponatremia (Na < 135 mEq/L), and TIPS in patients enrolled in A2ALL at the nine
participating centers, as well as in listed transplant candidates at the nine centers who were
not enrolled in the A2ALL study. Somewhat unexpectedly, there was no significant
difference in the frequency of these complications in those candidates for whom LDLT was
Berg et al. Page 7













seriously contemplated (i.e., for whom a donor was evaluated at their transplant center) and
in those who did not have such a donor. Despite this objective finding, there remains the
possibility that experienced transplant teams still may have applied some selection bias in
the recommendation of pursuit of LDLT in their centers such that the reported survival
benefit may not be universally obtained by all candidates. Given this possibility, one should
remain cautious about the generalized pursuit of LDLT in all candidates with low MELD
scores presenting to transplant centers. Future analyses of very large cohorts of LDLT
recipients may permit the further identification of subsets of candidates who receive
maximal benefit from this procedure.
The majority of transplant candidates in the A2ALL retrospective study(1) underwent both
listing and transplant prior to the initiation of the MELD-based liver allocation system. In
the current MELD era analysis, candidates who enrolled in A2ALL with MELD15+, who
did not have HCC, and who received LDLT, had markedly lower mortality compared to
those waiting for, or receiving DDLT (HR 0.42, 95% CI 0.26–0.69; p=0.0006). This
survival benefit was similar to that previously reported by our group(1) and strongly
supports the continued application of LDLT in this group of patients with higher MELD
scores. As there were only 27 patients enrolled in A2ALL in the post-MELD era with
MELD scores at enrollment of greater than 30, and only eight of these patients received
LDLT, we were unable to perform an analysis restricted to transplant candidates with very
high MELD scores and cannot comment on the presence or absence of possible futility
associated with LDLT in these high MELD candidates.
Fifteen percent of the patients in the current analysis carried a diagnosis of HCC. As detailed
in Table 1, patients who ultimately went on to receive LDLT were more likely to have stage
T3 or higher tumors than those who received DDLT, most likely as a consequence of
standardized (higher) exception MELD scores for those with stage T2 HCC, which
permitted relatively expeditious DDLT. It is of note that despite the relatively large
percentage of patients with T3 tumors, fairly quick access to DDLT was noted for the HCC
patients with lower laboratory MELD scores, such that wait times for DDLT for these
patients was far less than that for non-HCC candidates (7.9 months median wait for DDLT
for MELD<15 candidates without HCC who received DDLT versus 2.2 months median wait
for MELD<15 candidates with HCC). This wait time for DDLT for low MELD HCC
patients was similar to the wait time for LDLT in this group (median 1.6 months). In this
setting, the lack of a survival advantage associated with receipt of LDLT for low MELD
HCC transplant candidates was not surprising. Transplant candidates with MELD15+ with
HCC had significantly lower mortality with LDLT.
In summary, results from the A2ALL study in the MELD liver allocation era continued to
demonstrate significant survival advantage associated with receipt of LDLT in comparison
to continued waiting for DDLT. This survival benefit exists for patients with low laboratory
MELD scores and for patients with MELD scores of 15 and higher. These results justify a
continued role for LDLT in the U.S., especially in the context of a severe and ongoing
limitation in the supply of deceased donor organs and substantial waitlist mortality. The data
presented in this study should serve to guide the discussion that occurs between transplant
physicians and transplant candidates regarding the survival benefits associated with receipt
of a living donor liver transplant. With the identification and quantification of this survival
benefit, transplant candidates and centers may be better prepared to advocate for pursuit of
living donor liver transplantation in transplant candidates. Future efforts should focus on
delineating those transplant candidates that benefit most from receipt of LDLT, and on
identifying those patients for whom DDLT serves as the best avenue to successful
transplantation.
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A2ALL Adult to adult living donor liver transplant study
DDLT Deceased Donor Liver Transplant
DRI Donor risk index
HCC hepatocellular carcinoma
LDLT Living Donor Liver Transplant
MELD Model for End-stage Liver Disease
SRTR Scientific Registry for Transplant Recipients
TIPSS Transjugular intrahepatic portosystemic shunt
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Outcomes of A2ALL transplant candidates. The probability of LDLT, DDLT, death on the
waitlist or remaining alive without transplant over five years after first donor evaluation for
living donor candidates with a) MELD<15 at evaluation and b) MELD15+ at evaluation.
Estimates are based on the cumulative incidence function.
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Mortality for transplant candidates. Mortality following initial potential donor evaluation for
candidates without HCC according to MELD score at evaluation and whether LDLT was
performed or not. For graphical purposes, mortality while awaiting LDLT is assumed to be
the same as mortality for candidates for whom LDLT was not available up until the median
time for LDLT (3.0 months for MELD<15 and 2.5 months for MELD15+). Shown for
patient age=50, no HCC, with HCV, no other cholestatic disease, and MELD=10 at
enrollment for MELD<15 group and MELD=20 at enrollment for MELD 15+ group.
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